GABITRIL
What it isGAT-1 GABA-reuptake inhibitor; adjunctive treatment of focal seizures.
Why this oneNo other marketed antiepileptic uses selective GABA-transporter blockade.
What limits it⚑ It can provoke seizures or nonconvulsive status in people without epilepsy; dizziness, tremor, and CYP3A4 interactions also matter.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Partial seizures, adjunctive (enzyme-inducing AEDs) | Adults | 4 mg QD | 32-56 mg/day divided BID-QID | 56 mg/day |
| Partial seizures, adjunctive (enzyme-inducing AEDs) | Adolescents 12-18 yr | 4 mg QD | divided BID-QID | 32 mg/day |
Titration Increase by 4 mg at start of week 2, then by 4-8 mg at weekly intervals
Renal Undefined
Hepatic Undefined
Pregnancy Animal studies show teratogenicity; use in pregnancy only if clearly needed; encourage NAAED Pregnancy Registry enrollment
Lactation Undefined
NO BOXED WARNINGS
Principal riskIt provokes seizures in people without epilepsy
Cost, est. cash$10–$300/month
Generic entry2011
Legacy pregnancy categoryC
Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.

Open Tiagabine in the interactive console ↗

